| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SFA Stock Overview
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally.
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв4.50 |
| 52 Week High | лв4.80 |
| 52 Week Low | лв3.40 |
| Beta | 0.17 |
| 1 Month Change | 3.69% |
| 3 Month Change | 3.21% |
| 1 Year Change | 32.35% |
| 3 Year Change | 35.95% |
| 5 Year Change | -8.56% |
| Change since IPO | -27.27% |
Recent News & Updates
Shareholder Returns
| SFA | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0.4% | -3.0% | 0.4% |
| 1Y | 32.4% | -1.0% | 8.8% |
Return vs Industry: SFA exceeded the BG Pharmaceuticals industry which returned -1% over the past year.
Return vs Market: SFA exceeded the BG Market which returned 8.8% over the past year.
Price Volatility
| SFA volatility | |
|---|---|
| SFA Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in BG Market | 8.9% |
| 10% least volatile stocks in BG Market | 2.5% |
Stable Share Price: SFA is less volatile than 75% of BG stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: SFA's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 4,790 | Ognian Donev | https://www.sopharmagroup.com |
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company’s products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions.
Sopharma AD Fundamentals Summary
| SFA fundamental statistics | |
|---|---|
| Market Cap | лв547.84m |
| Earnings (TTM) | лв92.04m |
| Revenue (TTM) | лв1.63b |
6.0x
P/E Ratio0.3x
P/S RatioIs SFA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SFA income statement (TTM) | |
|---|---|
| Revenue | лв1.63b |
| Cost of Revenue | лв1.28b |
| Gross Profit | лв352.27m |
| Other Expenses | лв260.23m |
| Earnings | лв92.04m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jan 30, 2023
| Earnings per share (EPS) | 0.76 |
| Gross Margin | 21.62% |
| Net Profit Margin | 5.65% |
| Debt/Equity Ratio | 35.5% |
How did SFA perform over the long term?
See historical performance and comparison